FR2408347A1 - Solution pour infusion pour le traitement de l'encephalopathie hepatique et procede pour sa preparation - Google Patents

Solution pour infusion pour le traitement de l'encephalopathie hepatique et procede pour sa preparation

Info

Publication number
FR2408347A1
FR2408347A1 FR7831145A FR7831145A FR2408347A1 FR 2408347 A1 FR2408347 A1 FR 2408347A1 FR 7831145 A FR7831145 A FR 7831145A FR 7831145 A FR7831145 A FR 7831145A FR 2408347 A1 FR2408347 A1 FR 2408347A1
Authority
FR
France
Prior art keywords
solution
infusion
treatment
hepatic encephalopathy
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7831145A
Other languages
English (en)
Other versions
FR2408347B1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leopold and Co Chem Pharm Fabrik GmbH
Original Assignee
Leopold and Co Chem Pharm Fabrik GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leopold and Co Chem Pharm Fabrik GmbH filed Critical Leopold and Co Chem Pharm Fabrik GmbH
Publication of FR2408347A1 publication Critical patent/FR2408347A1/fr
Application granted granted Critical
Publication of FR2408347B1 publication Critical patent/FR2408347B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Abstract

LA PRESENTE INVENTION CONCERNE UNE SOLUTION POUR INFUSION. CETTE SOLUTION RENFERME COMME SEULE SUBSTANCE ACTIVE DE LA L-VALINE, AINSI EVENTUELLEMENT QU'UNE QUANTITE ALLANT AU MAXIMUM JUSQU'A 5 EN POIDS DE SUCRES ET(OU) D'ALCOOLS DERIVES DES SUCRES ET DES ADDITIFS USUELS FORMANT ELECTROLYTES. CETTE SOLUTION EST UTILISABLE POUR LE TRAITEMENT DE L'ENCEPHALOPATHIE HEPATIQUE. ELLE PERMET D'OBTENIR, ENTRE AUTRES PAR INFUSION DE LADITE SOLUTION, UN ECLAIRCISSEMENT RAPIDE DU SENSORIUM LORS DU COMA HEPATIQUE.
FR7831145A 1977-11-09 1978-11-03 Solution pour infusion pour le traitement de l'encephalopathie hepatique et procede pour sa preparation Granted FR2408347A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE2750159A DE2750159C3 (de) 1977-11-09 1977-11-09 Infusionslösung zur Behandlung von hepatischer Encephalopathie und ein Verfahren zu deren Herstellung

Publications (2)

Publication Number Publication Date
FR2408347A1 true FR2408347A1 (fr) 1979-06-08
FR2408347B1 FR2408347B1 (fr) 1981-06-26

Family

ID=6023374

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7831145A Granted FR2408347A1 (fr) 1977-11-09 1978-11-03 Solution pour infusion pour le traitement de l'encephalopathie hepatique et procede pour sa preparation

Country Status (11)

Country Link
US (1) US4259353A (fr)
JP (1) JPS5489014A (fr)
BE (1) BE871860A (fr)
CA (1) CA1103160A (fr)
CH (1) CH636766A5 (fr)
DE (1) DE2750159C3 (fr)
FR (1) FR2408347A1 (fr)
GB (1) GB2007503B (fr)
IT (1) IT1108758B (fr)
NL (1) NL7810654A (fr)
SE (1) SE7811446L (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1184499A (fr) * 1981-06-29 1985-03-26 David C. Madsen Compose nutritif pour le traitement de l'insuffisance hepatique
US5571783A (en) * 1993-03-09 1996-11-05 Clintec Nutrition Company Composition and method for treating patients with hepatic disease
AU2629895A (en) * 1994-06-23 1996-01-19 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for liver regeneration
US20040022827A1 (en) * 1997-09-30 2004-02-05 Chugai Seiyaku Kabusiki Kaisha Remedy for hepatopathy
US9101537B2 (en) 2008-07-25 2015-08-11 Reven Pharmaceuticals, Inc. Compositions and methods for the prevention and treatment of cardiovascular diseases
CN104997803B (zh) 2010-07-22 2019-07-09 雷文制药有限公司 包含使用磁偶极子稳定化溶液的治疗或改善疾病并增强表现的方法和组合物
JP7142284B2 (ja) * 2017-06-06 2022-09-27 株式会社らいむ 神経伸長促進剤

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2140M (fr) * 1961-04-25 1963-11-12 Ile D Etudes Et De Brevets Nov Solutions de plasmine stabilisées.
US3146166A (en) * 1960-08-26 1964-08-25 Distillers Co Yeast Ltd Cobalamin and amino acid compositions
FR2299023A1 (fr) * 1975-02-03 1976-08-27 Massachusetts Gen Hospital Compositions d'aminoacides
DE2629845A1 (de) * 1976-07-02 1978-01-05 Geb Graze Erika Graze Infusions- bzw. injektionsloesungen bzw. waessrige konzentrate zu deren bereitung zur therapeutischen restituion des zellulaeren energiestoffwechsels und der koerpereigenen regelfunktion

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3764703A (en) * 1969-11-07 1973-10-09 Astra Ab Amino acid mixture for use in treatment of uremic conditions
US3832465A (en) * 1971-12-09 1974-08-27 H Ghadimi Injectable amino acid composition commensurate to the anabolic need of the body and method of using same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3146166A (en) * 1960-08-26 1964-08-25 Distillers Co Yeast Ltd Cobalamin and amino acid compositions
FR2140M (fr) * 1961-04-25 1963-11-12 Ile D Etudes Et De Brevets Nov Solutions de plasmine stabilisées.
FR2299023A1 (fr) * 1975-02-03 1976-08-27 Massachusetts Gen Hospital Compositions d'aminoacides
DE2629845A1 (de) * 1976-07-02 1978-01-05 Geb Graze Erika Graze Infusions- bzw. injektionsloesungen bzw. waessrige konzentrate zu deren bereitung zur therapeutischen restituion des zellulaeren energiestoffwechsels und der koerpereigenen regelfunktion

Also Published As

Publication number Publication date
SE7811446L (sv) 1979-05-10
JPS5489014A (en) 1979-07-14
BE871860A (fr) 1979-05-08
US4259353A (en) 1981-03-31
CA1103160A (fr) 1981-06-16
CH636766A5 (de) 1983-06-30
FR2408347B1 (fr) 1981-06-26
JPS5729446B2 (fr) 1982-06-23
NL7810654A (nl) 1979-05-11
DE2750159C3 (de) 1980-05-22
DE2750159A1 (de) 1979-05-10
IT7869444A0 (it) 1978-10-24
GB2007503A (en) 1979-05-23
GB2007503B (en) 1982-03-17
DE2750159B2 (de) 1979-09-06
IT1108758B (it) 1985-12-09

Similar Documents

Publication Publication Date Title
Boyle et al. Volume of interfibre spaces in frog muscle and the calculation of concentrations in the fibre water
FR2372804A1 (fr) Derives d'amino-acides, en tant qu'agents anti-hypertension
Hilgemann et al. Activation-dependent cumulative depletions of extracellular free calcium in guinea pig atrium measured with antipyrylazo III and tetramethylmurexide.
FR2408347A1 (fr) Solution pour infusion pour le traitement de l'encephalopathie hepatique et procede pour sa preparation
TNSN86004A1 (fr) Compose pharmaceutiquement actif et procede pour sa preparation
Docherty et al. Evidence for neuro-effector transmission through postjunctional alpha 2-adrenoceptors in human saphenous vein.
DE3867764D1 (de) Volumenselektive spektroskopie mittels nachfokussierter echos.
Manthey Further studies of the effect of calcium on the time course of action of carbamylcholine at the neuromuscular junction
FR2374903A1 (fr) Nouvelle association utilisable en medecine veterinaire
FR2428839A1 (fr) Systeme d'electrodes ayant une electrode de reference depourvue de jonction liquide pour mesures voltametriques
White et al. Effect of elevated potassium on the ion content of mouse astrocytes and neurons
Jeschke et al. K+-dependent net Na+ efflux in roots of barley plants
Phillips The N-terminal groups of salmine
FR777824A (fr) Procédé pour la saccharification de la cellulose au moyen d'acides dilués, sous pression
Fraschini et al. Post-mortem increase of potassium in human cerebrospinal fluid
Hanretta et al. Properties of spontaneous and evoked release of taurine from hypothalamic crude P2 synaptosomal preparations
Wolman et al. Hyperoxia and formation of chromolipoid pigments
Bukoski et al. Differences in K+-induced relaxation of canine femoral and renal arteries
Penna et al. Relationship of changes in ionic concentrations to the augmentation produced by extra contractions in isolated mammalian ventricular muscle
SU101556A1 (ru) Способ определени готовности белого матта при бессемеровании медных штейнов
Kraus et al. In vitro Incorporation of Iron-59 into Hemoglobin S Visualized by Autoradiography.
Conway et al. Mode of action of chlorothiazide in the reduction of blood pressure in hypertension∗
FR2403470A1 (fr) Pompe a diaphragme
SU1153260A1 (ru) Способ диагностики воспалительных заболеваний в печени
SU473756A1 (ru) Сплав на основе свинца

Legal Events

Date Code Title Description
ST Notification of lapse